AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ISLAND PHARMACEUTICALS LTD

0.415

-0.005-1.19%

Volume:46.94K

Turnover:19.73K

Market Cap:111.66M

PE:-18.35

High:0.430

Open:0.430

Low:0.415

Close:0.420

52wk High:0.630

52wk Low:0.120

Shares:269.05M

Float Shares:110.76M

Volume Ratio:0.08

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.023

EPS(LYR):-0.023

ROE:-90.37%

ROA:-49.16%

PB:15.60

PE(LYR):-18.35

Loading ...

Overview Company News Filings

Island Pharmaceuticals Admits It Was Not Strictly in Compliance With ASX Listing Rules

MT Newswires Live

Island Pharmaceuticals Says US FDA Confirms Animal Model as Development Pathway for Antiviral Drug Candidate; Shares Rise 10%

MT Newswires Live

Island Pharmaceuticals to Raise AU$9 Million via Placement

MT Newswires Live

Island Pharmaceuticals Ltd - Placement of a$9 Mln at a$0.35 Each

THOMSON REUTERS

BRIEF-Island Pharmaceuticals Seeks Trading Halt

Island Pharmaceuticals Ltd - Seeks Trading Halt Pending FDA Feedback on Galidesivir Program

THOMSON REUTERS

Island Pharmaceuticals Limited's (ASX:ILA) Profit Outlook

Simply Wall St.

Island Pharmaceuticals Secures US Patent for Antiviral Drug Candidate; Shares Rise 12%

MT Newswires Live

Island Pharmaceuticals Ltd - US Patent Granted for Galidesivir in Filoviridae Viruses

THOMSON REUTERS

BRIEF-Island Pharmaceuticals Says FDA Advises It Requires Additional Time To Finalise Response To Co's Submission

Island Pharmaceuticals Says US FDA Needs More Time to Review Galidesivir Submission

MT Newswires Live

Island Pharmaceuticals - Co Had Sought Further Clarification on Galidesivir's Development Pathway Under FDA's Animal Rule

THOMSON REUTERS

Island Pharmaceuticals - FDA Advises It Requires Additional Time to Finalise Response to Co's Recent Submission

THOMSON REUTERS

Island Pharmaceuticals Enters Master Service Agreement With Texas Biomedical to Advance Development of Antiviral Molecule

MT Newswires Live

Island Pharmaceuticals Secures US Patent for Antiviral Drug; Shares Rise 7%

MT Newswires Live

Island Pharmaceuticals Secures Over AU$1 Million in New Funding

MT Newswires Live

Island Pharmaceuticals Secures Membership to Medical Countermeasures Coalition, Shares Reach All-Time Peak

MT Newswires Live

Island Pharmaceuticals Says FDA Confirms Animal Rule Pathway Appropriate for Approval of Marburg Virus Countermeasures, Shares Reach All-Time Peak

MT Newswires Live

BUZZ-Australia's Island Pharmaceuticals hits record high on regulatory progress with FDA

BRIEF-Island Pharmaceuticals Seeks Trading Halt

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ILA.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ILA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","market":"AU","secType":"STK","nameCN":"ISLAND PHARMACEUTICALS LTD","latestPrice":0.415,"timestamp":1770698178144,"preClose":0.42,"halted":0,"volume":46939,"delay":0,"changeRate":-0.011904761904761916,"nameEN":"ISLAND PHARMACEUTICALS LTD","floatShares":110756995,"shares":269052397,"eps":-0.022614,"marketStatus":"Trading","change":-0.005,"latestTime":"02-10 15:38:15 AEDT","open":0.43,"high":0.43,"low":0.415,"amount":19734,"amplitude":0.035714,"askPrice":0.415,"askSize":7488,"bidPrice":0.41,"bidSize":10806,"shortable":3,"etf":0,"ttmEps":-0.022614,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770699600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.42,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.080451,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ILA.AU\",,,,,undefined,":{"symbol":"ILA.AU","floatShares":110756995,"roa":"-49.16%","roe":"-90.37%","lyrEps":-0.022614,"volumeRatio":0.080451,"shares":269052397,"dividePrice":0,"high":0.43,"amplitude":0.035714,"preClose":0.42,"low":0.415,"week52Low":0.12,"pbRate":"15.60","psRate":"939.00","week52High":0.63,"institutionHeld":0,"latestPrice":0.415,"committee":0.181371,"eps":-0.022614,"divideRate":0,"volume":46939,"delay":0,"ttmEps":-0.022614,"open":0.43,"prevYearClose":0.43,"prevWeekClose":0.42,"prevMonthClose":0.39,"prevQuarterClose":0.43,"fiveDayClose":0.39,"twentyDayClose":0.45,"sixtyDayClose":0.425,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ILA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ILA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ILA.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610692919","title":"Island Pharmaceuticals Admits It Was Not Strictly in Compliance With ASX Listing Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2610692919","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610692919?lang=en_us&edition=fundamental","pubTime":"2026-02-10 12:29","pubTimestamp":1770697763,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals (ASX:ILA) said that its conduct was not strictly in compliance with the Australian Securities Exchange Listing Rule 15.7, adding that it \"was unintentional, and is regrettable,\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2608382642","title":"Island Pharmaceuticals Says US FDA Confirms Animal Model as Development Pathway for Antiviral Drug Candidate; Shares Rise 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608382642","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608382642?lang=en_us&edition=fundamental","pubTime":"2026-02-04 08:49","pubTimestamp":1770166184,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  said the US Food and Drug Administration confirmed its proposed animal model as the development pathway for its antiviral drug candidate, Galidesivir, according to a Wednesday filing with the Australian bourse.The US FDA confirmed the core elements of the proposed animal model, including the use of the Angola strain of Marburg, and outlined the final steps required to develop Galidesivir toward approval under the Animal Rule, the filing said.Under the two-stage clinical development pathway, the company will start targeted dose optimization and pharmacokinetic studies using the first manufactured batch of Galidesivir, the filing added.Shares of the company rose past 10% in recent Wednesday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2608389259","title":"Island Pharmaceuticals to Raise AU$9 Million via Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2608389259","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608389259?lang=en_us&edition=fundamental","pubTime":"2026-02-04 07:18","pubTimestamp":1770160692,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  received firm commitments to raise AU$9 million via a placement of 25.7 million shares at an issue price of AU$0.35 per share, according to a Wednesday filing with the Australian bourse.The offer price represents a 17.9% discount to the stock's 15-day volume weighted average price, the filing said.The new shares are expected to settle on Feb.13, the filing added.Funds raised will be used to advance the company's antiviral drug Galidesivir to approval under the US Food & Drug Administration's  Animal Rule.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2608038615","title":"Island Pharmaceuticals Ltd - Placement of a$9 Mln at a$0.35 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2608038615","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608038615?lang=en_us&edition=fundamental","pubTime":"2026-02-04 06:34","pubTimestamp":1770158093,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nFWN3YZ1A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2608588466","title":"BRIEF-Island Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2608588466","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608588466?lang=en_us&edition=fundamental","pubTime":"2026-02-02 05:44","pubTimestamp":1769982261,"startTime":"0","endTime":"0","summary":"BRIEF-Island Pharmaceuticals Seeks Trading HaltFeb 2 (Reuters) - Island Pharmaceuticals ILA.AX:SEEKS TRADING HALT PENDING FDA FEEDBACK ON GALIDESIVIR PROGRAMFurther company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YV1SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2608657884","title":"Island Pharmaceuticals Ltd - Seeks Trading Halt Pending FDA Feedback on Galidesivir Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2608657884","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608657884?lang=en_us&edition=fundamental","pubTime":"2026-02-02 05:43","pubTimestamp":1769982238,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260201:nFWN3YV1SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2607775642","title":"Island Pharmaceuticals Limited's (ASX:ILA) Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2607775642","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607775642?lang=en_us&edition=fundamental","pubTime":"2026-01-29 04:41","pubTimestamp":1769632871,"startTime":"0","endTime":"0","summary":"With the business potentially at an important milestone, we thought we'd take a closer look at Island Pharmaceuticals...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ila/island-pharmaceuticals-shares/news/island-pharmaceuticals-limiteds-asxila-profit-outlook","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ila/island-pharmaceuticals-shares/news/island-pharmaceuticals-limiteds-asxila-profit-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2601416688","title":"Island Pharmaceuticals Secures US Patent for Antiviral Drug Candidate; Shares Rise 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601416688","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601416688?lang=en_us&edition=fundamental","pubTime":"2026-01-07 08:17","pubTimestamp":1767745051,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  received a patent from the US Patent and Trademark Office for the use of its antiviral drug, galidesivir, for the potential treatment of filoviridae viruses, including Marburg and Ebola, according to a Wednesday filing with the Australian bourse.The US patent provides the company with protection to pursue treatment options for viruses from the filoviridae family using galidesivir until Oct. 14, 2031, the filing said.Shares of the company rose 12% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2601846130","title":"Island Pharmaceuticals Ltd - US Patent Granted for Galidesivir in Filoviridae Viruses","url":"https://stock-news.laohu8.com/highlight/detail?id=2601846130","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601846130?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:45","pubTimestamp":1767739515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nFWN3Y7168:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2601073219","title":"BRIEF-Island Pharmaceuticals Says FDA Advises It Requires Additional Time To Finalise Response To Co's Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2601073219","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601073219?lang=en_us&edition=fundamental","pubTime":"2026-01-05 09:18","pubTimestamp":1767575885,"startTime":"0","endTime":"0","summary":"BRIEF-Island Pharmaceuticals Says FDA Advises It Requires Additional Time To Finalise Response To Co's SubmissionJan 5  - Island Pharmaceuticals Ltd ILA.AX:FDA ADVISES IT REQUIRES ADDITIONAL TIME TO FINALISE RESPONSE TO CO'S RECENT SUBMISSIONCO HAD SOUGHT FURTHER CLARIFICATION ON GALIDESIVIR'S DEVELOPMENT PATHWAY UNDER FDA'S ANIMAL RULEFurther company coverage: ILA.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nFWN3Y3020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2601360073","title":"Island Pharmaceuticals Says US FDA Needs More Time to Review Galidesivir Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360073","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360073?lang=en_us&edition=fundamental","pubTime":"2026-01-05 08:54","pubTimestamp":1767574442,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  said the US Food and Drug Administration  needs additional time to respond to its recent submission on the clinical development of galidesivir under the animal rule, according to a Monday Australian bourse filing.Galidesivir is a clinical-stage molecule being developed for use against various viruses, including Ebola and yellow fever.The US FDA has not raised any concerns or requested additional information, and the company continues to engage in constructive dialogue, per the filing.The company is advancing preparatory work, including organizing a non-human primate study and coordinating with US government stakeholders, and is prepared to implement FDA guidance and move forward with study initiation once approval is granted, the filing added.The company's shares rose 2% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2601614022","title":"Island Pharmaceuticals - Co Had Sought Further Clarification on Galidesivir's Development Pathway Under FDA's Animal Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2601614022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601614022?lang=en_us&edition=fundamental","pubTime":"2026-01-05 05:42","pubTimestamp":1767562955,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260104:nFWN3Y3020:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2601202261","title":"Island Pharmaceuticals -  FDA Advises It Requires Additional Time to Finalise Response to Co's Recent Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2601202261","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601202261?lang=en_us&edition=fundamental","pubTime":"2026-01-05 05:42","pubTimestamp":1767562955,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260104:nFWN3Y3020:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2592954352","title":"Island Pharmaceuticals Enters Master Service Agreement With Texas Biomedical to Advance Development of Antiviral Molecule","url":"https://stock-news.laohu8.com/highlight/detail?id=2592954352","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592954352?lang=en_us&edition=fundamental","pubTime":"2025-12-17 09:28","pubTimestamp":1765934919,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals (ASX:ILA) secured a master service agreement with Texas Biomedical Research Institute, a biosafety level 4 facility in the US that can conduct preclinical infectious disease res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","BK7096"],"gpt_icon":0},{"id":"2589273853","title":"Island Pharmaceuticals Secures US Patent for Antiviral Drug; Shares Rise 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589273853","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589273853?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:27","pubTimestamp":1764890854,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  received a patent from the US Patent and Trademark Office for the use of its antiviral drug, Galidesivir, in the treatment of COVID-19, according to a Friday filing with the Australian bourse.The US patent provides the company with protection to pursue treatment options for COVID-19 infections using Galidesivir until July 18, 2042, the filing said.Shares of the company rose 7% in recent Friday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2588096797","title":"Island Pharmaceuticals Secures Over AU$1 Million in New Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2588096797","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588096797?lang=en_us&edition=fundamental","pubTime":"2025-12-03 11:00","pubTimestamp":1764730846,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  has secured over AU$1 million through the exercise of 14.4 million options at AU$0.07 each by existing and substantial shareholders, according to a Wednesday Australian bourse filing.The funds will be used to drive regulatory initiatives under the US Food and Drug Administration animal rule pathway and support US government engagement to position Galidesivir for inclusion in national stockpiles as a key antiviral countermeasure, the filing added.The company's shares fell 2% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2585860434","title":"Island Pharmaceuticals Secures Membership to Medical Countermeasures Coalition, Shares Reach All-Time Peak","url":"https://stock-news.laohu8.com/highlight/detail?id=2585860434","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585860434?lang=en_us&edition=fundamental","pubTime":"2025-11-24 10:06","pubTimestamp":1763949972,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  secured membership to the medical countermeasures coalition, an international coalition of non-profit organizations, academic groups, and industry partners focusing on medical countermeasures, including vaccines, therapeutics, diagnostics, and related technologies, according to a Monday Australian bourse filing.The membership is expected to help advance the firm's Galidesivir antiviral molecule program, preceding pending regulatory, clinical, and stockpiling opportunities.Its shares jumped 14% in recent trading on Monday, earlier reaching an all-time peak.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","SKIS","ILA.AU"],"gpt_icon":0},{"id":"2584163296","title":"Island Pharmaceuticals Says FDA Confirms Animal Rule Pathway Appropriate for Approval of Marburg Virus Countermeasures, Shares Reach All-Time Peak","url":"https://stock-news.laohu8.com/highlight/detail?id=2584163296","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584163296?lang=en_us&edition=fundamental","pubTime":"2025-11-17 12:26","pubTimestamp":1763353565,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals  said that the US Food and Drug Administration  confirmed, in response to questions posed in a Type C meeting request, that the animal rule pathway is appropriate for the approval of Marburg virus countermeasures, and that its antiviral drug candidate Galidesivir would qualify for a tropical disease priority review voucher on approval, according to a Monday Australian bourse filing.The animal rule allows drugs to be approved based on efficacy demonstrated in well-controlled animal studies when human trials are unethical or not feasible.The regulator provided guidance on the clinical program design. The company will incorporate all the US FDA guidance into Galidesivir's clinical development pathway.The firm plans to begin the Galidesivir clinical trial program to advance approval in the first quarter of 2026. It has the opportunity to submit questions to the US FDA by Dec. 2.Its shares jumped 24% in recent trading on Monday, earlier reaching an all-time high.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ILA.AU","SKIS","BK7096"],"gpt_icon":0},{"id":"2584299615","title":"BUZZ-Australia's Island Pharmaceuticals hits record high on regulatory progress with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2584299615","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584299615?lang=en_us&edition=fundamental","pubTime":"2025-11-17 12:05","pubTimestamp":1763352307,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Island Pharmaceuticals hits record high on regulatory progress with FDA** Shares of Australia's Island Pharmaceuticals ILA.AX rise as much as 42.4% to record high of A$0.605** Antiviral drug development co says it received positive responses from US Food & Drug Administration to questions on approval for co's antiviral drug - Galidesivir - and its eligibility for a priority review voucher ** The priority review voucher, which has historically sold on the open market for between $100 mln and $155 mln, would boost Galidesivir's commercial value - co** Co says FDA confirmed the Animal Rule pathway is appropriate for Marburg virus countermeasures, allowing approval based on animal efficacy data rather than human trials, accelerating approval timeline ** YTD, stock has more than tripled in value   ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nL6N3WT05Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"gpt_icon":0},{"id":"2583538279","title":"BRIEF-Island Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2583538279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583538279?lang=en_us&edition=fundamental","pubTime":"2025-11-13 09:33","pubTimestamp":1762997614,"startTime":"0","endTime":"0","summary":"BRIEF-Island Pharmaceuticals Seeks Trading HaltNov 13 (Reuters) - Island Pharmaceuticals Ltd ILA.AX:TRADING HALTSEEKS TRADING HALT PENDING FDA FEEDBACK ON GALIDESIVIR PROGRAMFurther company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUEB7WSVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","ILA.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}]}}